Vaccines for the leishmaniases: Proposals for a research Agenda

PLoS Neglected Tropical Diseases

Volumn 5, Issue 3, 2011, Pages

  Costa, Carlos Henrique Nery ^a   Peters, Nathan C ^b   Maruyama, Sandra Regina ^c   de Brito Jr , Eldo Cardoso ^a   Santos, Isabel Kinney Ferreira de Miranda ^c,d   Ali, Nahid ^e   Brodskyn, Cláudia ^f   Campos Neto, Antônio ^g   Carvalho, Edgar M ^h   Chang, Kwang Poo ⁱ   Fernandes, Ana Paula ^j   Fujiwara, Ricardo ^j   Gazzinelli, Ricardo ^f,j   Goto, Hiro ^c   Grimaldi, Gabriel ^f   Kaye, Paul ^k   Kedzierski, Lukasz ^l   Khamesipour, Ali ^m   Maia, Carla ⁿ   Robert McMaster, W ^o   Mendonça, Sérgio C F ^f   Nakhasi, Hira Lal ^p   Piazza, Franco ^q   Quinnell, Rupert ^r   Reis, Alexandre Barbosa ^s   Santos Gomes, Gabriela ⁿ   Shaw, Jeffrey ^c   Valenzuela, Jesus ^b   Walden, Peter ^t   Werneck, Guilherme ^f   more..

^a FEDERAL UNIVERSITY OF PIAUÍ   (Brazil)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d EMBRAPA RECURSOS GENÉTICOS E BIOTECNOLOGIA   (Brazil)

^e INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^f INSTITUTO OSWALDO CRUZ   (Brazil)

^g FORSYTH INSTITUTE   (United States)

^h FEDERAL UNIVERSITY OF BAHIA   (Brazil)

ⁱ ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^j FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^k UNIVERSITY OF YORK   (United Kingdom)

^l WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^m TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

ⁿ INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^o UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^p CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^q INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^r UNIVERSITY OF LEEDS   (United Kingdom)

^s FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^t CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOLIPID; LEISHMANIA VACCINE; LIVE VACCINE; PARASITE ANTIGEN; PROTEOPHOSPHOGLYCAN; SALIVA PROTEIN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ARTICLE; CROSS PROTECTION; CYTOKINE RESPONSE; DISEASE CARRIER; GEOGRAPHIC DISTRIBUTION; GREENHOUSE EFFECT; HUMAN; IMMUNOMODULATION; INFECTION CONTROL; INFECTION RESISTANCE; LEISHMANIASIS; NONHUMAN;

EID: 79953794775     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000943     Document Type: Article

References (41)

1. Special Programme for Research and Training in Tropical Diseases (2010) Research to support the elimination of visceral leishmaniasis-annual report 2009. TDR/BL10.10 Geneva: World Health Organization. Available: http://apps.who.int/tdr/publications/about-tdr/annual-reports/bl10-annual-report/pdf/bl10-annual-report-2009.pdf. Accessed 4 March 2011.
2. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in leishmaniasis. Clin Microbiol Rev 19: 111-126.
3. Dantas-Torres F, (2007) The role of dogs as reservoirs of Leishmania parasites, with emphasis on Leishmania (Leishmania) infantum and Leishmania (Viannia) braziliensis. Vet Parasitol 149: 139-146.
4. Randolph SE, (2010) To what extent has climate change contributed to the recent epidemiology of tick-borne diseases? Vet Parasitol 167: 92-94.
5. Costa CH, (2008) Characterization and speculations on the urbanization of visceral leishmaniasis in Brazil. Cad Saude Publica 24: 2959-2963.
6. Senior K, (2008) Vector-borne diseases threaten Europe. Lancet Infect Dis 8: 531-532.
7. Okwor I, Uzonna J, (2009) Vaccines and vaccination strategies against human cutaneous leishmaniasis. Hum Vaccin 5: 291-301.
8. Nadim A, Javadian E, Tahvildar-Bidruni G, Ghorbani M, (1983) Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull Soc Pathol Exot Filiales 76: 377-383.
9. Anderson CF, Mendez S, Sacks DL, (2005) Nonhealing infection despite Th1 polarization produced by a strain of Leishmania major in C57BL/6 mice. J Immunol 174: 2934-2941.
10. Anderson CF, Oukka M, Kuchroo VJ, Sacks D, (2007) CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 204: 285-297.
11. Follador I, Araujo C, Bacellar O, Araujo CB, Carvalho LP, et al. (2002) Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis 34: E54-E58.
12. Maglione PJ, Chan J, (2009) How B cells shape the immune response against Mycobacterium tuberculosis. Eur J Immunol 39: 676-686.
13. Casadevall A, Pirofski LA, (2006) A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol 91: 1-44.
14. Hoerauf A, Solbach W, Lohoff M, Rollinghoff M, (1994) The Xid defect determines an improved clinical course of murine leishmaniasis in susceptible mice. Int Immunol 6: 1117-1124.
15. Moreno I, Molina R, Torano A, Laurin E, Garcia E, et al. (2007) Comparative real-time kinetic analysis of human complement killing of Leishmania infantum promastigotes derived from axenic culture or from Phlebotomus perniciosus. Microbes Infect 9: 1574-1580.
16. Bourdoiseau G, Hugnet C, Goncalves RB, Vezilier F, Petit-Didier E, et al. (2009) Effective humoral and cellular immunoprotective responses in Li ESAp-MDP vaccinated protected dogs. Vet Immunol Immunopathol 128: 71-78.
17. Buxbaum LU, Thomas BN, (2009) IgG1, but not IgG2a/c, is pathogenic in Leishmania mexicana infection. J Immunol 182: 133.18.
18. Woelbing F, Kostka SL, Moelle K, Belkaid Y, Sunderkoetter C, et al. (2006) Uptake of Leishmania major by dendritic cells is mediated by Fcgamma receptors and facilitates acquisition of protective immunity. J Exp Med 203: 177-188.
19. Gibson-Corley KN, Boggiatto PM, Mukbel RM, Petersen CA, Jones DE, (2010) A deficiency in the B cell response of C57BL/6 mice correlates with loss of macrophage-mediated killing of Leishmania amazonensis. Int J Parasitol 40: 157-161.
20. Kedzierski L, Zhu Y, Handman E, (2006) Leishmania vaccines: progress and problems. Parasitology 133 (Suppl): S87-S112.
21. Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, et al. (2000) Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356: 1565-1569.
22. Campos-Neto A, (2005) What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery? Braz J Med Biol Res 38: 979-984.
23. Julia V, Rassoulzadegan M, Glaichenhaus N, (1996) Resistance to Leishmania major induced by tolerance to a single antigen. Science 274: 421-423.
24. Nylén S, Akuffo H, (2009) Tracing immunity to human leishmaniasis. Future Microbiol 4: 241-254.
25. Cohen J, (2009) AIDS vaccine research. HIV natural resistance field finally overcomes resistance. Science 326: 1476-1477.
26. Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Ferrer L, (2008) Canine leishmaniosis-new concepts and insights on an expanding zoonosis: part one. Trends Parasitol 24: 324-330.
27. Mendez S, Tabbara K, Belkaid Y, Bertholet S, Verthelyi D, et al. (2003) Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability. Infect Immun 71: 5121-5129.
28. Davoudi N, Tate CA, Warburton C, Murray A, Mahboudi F, et al. (2005) Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials. Vaccine 23: 1170-1177.
29. Zijlstra EE, el-Hassan AM, Ismael A, Ghalib HW, (1994) Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 51: 826-836.
30. Okwor I, Uzonna J, (2008) Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. Immunol Res 41: 123-136.
31. Collin N, Gomes R, Teixeira C, Cheng L, Laughinghouse A, et al. (2009) Sand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania. PLoS Pathog 5: e1000441 doi:10.1371/journal.ppat.1000441.
32. Oliveira F, Jochim RC, Valenzuela JG, Kamhawi S, (2009) Sand flies, Leishmania and transcriptome-borne solutions. Parasitol Int 58: 1-5.
33. Rogers ME, Ilg T, Nikolaev AV, Ferguson MA, Bates PA, (2004) Transmission of cutaneous leishmaniasis by sand flies is enhanced by regurgitation of fPPG. Nature 430: 463-467.
34. Rogers M, Kropf P, Choi BS, Dillon R, Podinovskaia M, et al. (2009) Proteophosophoglycans regurgitated by Leishmania-infected sand flies target the L-arginine metabolism of host macrophages to promote parasite survival. PLoS Pathog 5: e1000555 doi:10.1371/journal.ppat.1000555.
35. Rogers ME, Sizova OV, Ferguson MA, Nikolaev AV, Bates PA, (2006) Synthetic glycovaccine protects against the bite of leishmania-infected sand flies. J Infect Dis 194: 512-518.
36. Peters NC, Kimblin N, Secundino N, Kamhawi S, Lawyer P, Sacks DL, (2009) Vector transmission of leishmania abrogates vaccine-induced protective immunity. PLoS Pathog. 5: e1000484 doi:10.1371/journal.ppat.1000484.
37. Crotty S, (2009) Shane Crotty: exploring immune memory. Interview by Kira Heller. J Exp Med 206: 974-975.
38. Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, et al. (2001) Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 69: 4103-4108.
39. Chaudhuri R, Ahmed S, Ansari FA, Singh HV, Ramachandran S, (2008) MalVac: database of malarial vaccine candidates. Malar J 7: 184.
40. Carlton JM, Escalante AA, Neafsey D, Volkman SK, (2008) Comparative evolutionary genomics of human malaria parasites. Trends Parasitol 24: 545-550.
41. Azizi H, Hassani K, Taslimi Y, Najafabadi HS, Papadopoulou B, et al. (2009) Searching for virulence factors in the non-pathogenic parasite to humans Leishmania tarentolae. Parasitology 136: 723-735.